MLAB Stock Analysis: Mesa Laboratories | NASDAQ
Scientific & Technical Instruments | NASDAQ, USA | Market Cap: 534m USD | 12M Return: 44.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.7M
EPS Trend: -36.6%
Qual. Beats: 0
Rev. Trend: 95.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Mesa Laboratories, Inc. (NASDAQ: MLAB) is a Lakewood, Colorado-based company that develops, manufactures, and services life sciences tools and quality control products across four operating segments: Sterilization and Disinfection Control (biological and chemical indicators for pharma, medical device, and healthcare settings), Clinical Genomics (the MassARRAY genetic analysis platform and related consumables), Biopharmaceutical Development (Gyrolab immunoassay systems and PurePep peptide synthesis instruments), and Calibration Solutions (quality control instruments sold under the DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands). Founded in 1982 and public since 1995, Mesa sells globally with operations in North America, Europe, and Asia Pacific.
The business model follows a typical life sciences tools structure, combining capital equipment (such as MassARRAY systems, Gyrolab xPand/xPlore, and PurePep Chorus/Synthesis instruments) with recurring consumables revenue from reagent kits, microfluidic disks, chemical indicators, and calibration consumables. As a small-cap Health Care company in the GICS Life Sciences Tools & Services sub-industry, Mesa serves regulated end markets-including pharmaceutical manufacturing, clinical laboratories, hospitals, and medical device production-where validation and quality control are mandatory, which tends to support demand stability for its indicator and calibration products.
- Sterilization Disinfection Control segment drives revenue from pharma healthcare demand
- Biopharmaceutical Development growth depends on Gyrolab and peptide synthesis adoption
- Clinical Genomics MassARRAY faces competition from next-generation sequencing platforms
| Net Income: 6.71m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 0.25 > 1.0 |
| NWC/Revenue: 17.81% < 20% (prev -25.43%; Δ 43.24% < -1%) |
| CFO/TA 0.10 > 3% & CFO 42.8m > Net Income 6.71m |
| Net Debt (131.9m) to EBITDA (43.4m): 3.04 < 3 |
| Current Ratio: 1.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.54m) vs 12m ago 2.12% < -2% |
| Gross Margin: 63.53% > 18% (prev 62.61%; Δ 0.92% > 0.5%) |
| Asset Turnover: 57.86% > 50% (prev 55.61%; Δ 2.26% > 0%) |
| Interest Coverage Ratio: 1.88 > 6 (EBIT TTM 20.1m / Interest Expense TTM 10.7m) |
| A: 0.10 (Total Current Assets 106.3m - Total Current Liabilities 61.9m) / Total Assets 427.7m |
| B: -0.43 (Retained Earnings -185.7m / Total Assets 427.7m) |
| C: 0.05 (EBIT TTM 20.1m / Avg Total Assets 430.5m) |
| D: 0.77 (Book Value of Equity 186.2m / Total Liabilities 241.5m) |
| Altman-Z'' = 0.39 = B |
| DSRI: 1.02 (Receivables 44.1m/42.0m, Revenue 249.1m/241.0m) |
| GMI: 0.99 (GM 62.61% / 63.53%) |
| AQI: 0.99 (AQ_t 0.68 / AQ_t-1 0.69) |
| SGI: 1.03 (Revenue 249.1m / 241.0m) |
| TATA: -0.08 (NI 6.71m - CFO 42.8m) / TA 427.7m) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of July 22, 2026, the stock is trading at USD 97.51 with a total of 115,854 shares traded. Over the past week, the price has changed by +3.03%, over one month by +4.59%, over three months by -3.92% and over the past year by +44.55%.
Current recommended Stop Loss: 83.60 (which is 14.3% or 2.7 ATR below the current price).
Mesa Laboratories has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold MLAB.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 112 | 14.9% |
P/E Trailing = 80.5583
P/E Forward = 35.2113
P/S = 2.1438
P/B = 2.9024
Revenue TTM = 249.1m USD
EBIT TTM = 20.1m USD
EBITDA TTM = 43.4m USD
Long Term Debt = 145.9m USD (from longTermDebt, last quarter)
Short Term Debt = 9.31m USD (from shortTermDebt, last quarter)
Debt = 158.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.69m
Net Debt = 131.9m USD (calculated: Debt 158.9m - CCE 26.9m)
Enterprise Value = 666.0m USD (534.1m + Debt 158.9m - CCE 26.9m)
Interest Coverage Ratio = 1.88 (Ebit TTM 20.1m / Interest Expense TTM 10.7m)
EV/FCF = 15.55x (Enterprise Value 666.0m / FCF TTM 42.8m)
FCF Yield = 6.43% (FCF TTM 42.8m / Enterprise Value 666.0m)
FCF Margin = 17.19% (FCF TTM 42.8m / Revenue TTM 249.1m)
Net Margin = 2.69% (Net Income TTM 6.71m / Revenue TTM 249.1m)
Gross Margin = 63.53% ((Revenue TTM 249.1m - Cost of Revenue TTM 90.9m) / Revenue TTM)
Gross Margin QoQ = 73.21% (prev 64.18%)
Tobins Q-Ratio = 1.56 (Enterprise Value 666.0m / Total Assets 427.7m)
Interest Expense / Debt = 6.73% (Interest Expense 10.7m / Debt 158.9m)
Taxrate = 44.13% (5.30m / 12.0m)
NOPAT = 11.2m (EBIT 20.1m * (1 - 44.13%))
Current Ratio = 1.72 (Total Current Assets 106.3m / Total Current Liabilities 61.9m)
Debt / Equity = 0.85 (Debt 158.9m / totalStockholderEquity, last quarter 186.2m)
Debt / EBITDA = 3.04 (Net Debt 131.9m / EBITDA 43.4m)
Debt / FCF = 3.08 (Net Debt 131.9m / FCF TTM 42.8m)
Total Stockholder Equity = 181.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.56% (Net Income 6.71m / Total Assets 427.7m)
RoE = 3.71% (Net Income TTM 6.71m / Total Stockholder Equity 181.0m)
RoCE = 6.15% (EBIT 20.1m / Capital Employed (Equity 181.0m + L.T.Debt 145.9m))
RoIC = 3.10% (NOPAT 11.2m / Invested Capital 362.7m)
WACC = 8.47% (E(534.1m)/V(693.0m) * Re(9.87%) + D(158.9m)/V(693.0m) * Rd(6.73%) * (1-Tc(0.44)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.25 | Cagr: 1.21%
[DCF] Terminal Value 75.18% ; FCFF base≈42.6m ; Y1≈43.2m ; Y5≈46.7m
[DCF] Fair Price = 104.8 (EV 711.0m - Net Debt 131.9m = Equity 579.1m / Shares 5.52m; r=8.47% [WACC]; 5y FCF grow 1.23% → 2.50% )
EPS Correlation: -36.60 | EPS CAGR: -13.20% | SUE: 0.34 | # QB: 0
Revenue Correlation: 95.19 | Revenue CAGR: 6.58% | SUE: -0.82 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.55 | Chg30d=+140.57% | Revisions=+25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=2.73 | Chg30d=+116.67% | Revisions=+25% | Analysts=1
EPS current Year (2027-03-31): EPS=11.62 | Chg30d=+115.58% | Revisions=+25% | GrowthEPS=+39.3% | GrowthRev=+4.0%
EPS next Year (2028-03-31): EPS=12.27 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+5.6% | GrowthRev=+5.0%